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We present the case of an 8-year-old male with an intestinal obstruction and a simultaneous incidental
adrenal mass. The patient had a newborn history of intestinal obstruction secondary to ileal atresia.
Intestinal length at the time of operation was measured to be 50% of predicted. The patient’s present
intestinal obstruction presented a challenge to the evaluation and management of a concurrent adrenal
mass.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Case report
The patient is an otherwise healthy 8-year-old male who pre-
sented with a 4 day period of worsening abdominal pain and
vomiting. At the time of repair of a type IIIa jejunal atresia on day of
life 1 he was noted to have 110 cm of small bowel and an intact
ileocecal valve. He had no signs or symptoms consistent with a
hormonally active adrenal mass, speciﬁcally headaches, palpita-
tions, or hypertension.
In the emergency department he was found to be ill appearing
and tachycardic with heart rate of 106 and blood pressure of 111/78.
He was small for his age (19th and 8th percentile for height and
weight, respectively). His mucous membranes were dry and he was
unable to void. His abdomen was distended and tender in bilateral
lower quadrants but peritoneal signs were not present.
Admission labs showed hypochloremia and prerenal azotemia
with serum chloride of 89 and blood urea nitrogen of 33. His white
blood cell count was normal at 12 and his anion gap was 16. An
abdominal series was consistent with intestinal obstruction. A CT, christopher.pennell@gmail.
 Inc. Open access under CC BY-NC-NDscan was conﬁrmatory of obstruction and also revealed a 6 cm left
adrenal mass (Fig. 1).
Intravenous ﬂuids were administered to correct the patient’s
hypovolemia and a nasogastric tube was inserted to alleviate the
patient’s vomiting. Urine vanillylmandelic acid (VMA) and cate-
cholamines were sent to evaluate the mass for metabolic activity.
The patient’s tenderness improved with NG decompression but
continued to wax and wane; the bilious NG tube output increased
signiﬁcantly over the course of 24 h.With the patient’s prior history
of foreshortened intestinal length and a lack of clinical improve-
ment we elected to address the obstruction operatively.
Preoperatively anesthesia placed an arterial line and had alpha-
blocking agents available in the operating room for management of
a possible hypertensive crisis.
The surgery was performed through a supraumbilical midline
laparotomy. A lysis of adhesions was performed ﬁrst as the intes-
tinal obstructionwas the immediate concern. A transition point was
noted at the site of the prior anastomosis where an obstruction
resulted from an internal hernia. There was no evidence of intes-
tinal ischemia and all bowel was patent following lysis of adhesions.
The left adrenal gland was then exposed. Gentle compression of the
mass was performed and the patient’s blood pressure was observed
to remain stable. As such, a left adrenalectomy was performed.
Numerous 1e2 cm periaortic and mesenteric lymph nodes were
noted and biopsied as part of staging for a possible malignancy.
Throughout the operation the patient’s heart rate and blood pres-
sure remained stable. license.
Fig. 1. Computed tomography scan showing the patient’s concurrent adrenal mass and
intestinal obstruction.
Table 1
International Neuroblastoma Staging System.
Stage Deﬁnition
1 Localized tumor with complete gross excision, with or
without microscopic residual disease; representative ipsilateral
lymph nodes negative for tumor microscopically (nodes attached
to and removed with the primary tumor may be positive)
2A Localized tumor with incomplete gross excision; representative
ipsilateral nonadherent lymph nodes negative for
tumor microscopically
2B Localized tumor with or without complete gross excision, with
ipsilateral nonadherent lymph nodes positive for tumor.
Enlarged contralateral nodes must be negative microscopically
3 Unresectable unilateral tumor inﬁltrating across the midline
with or without regional lymph node involvement; or localized
unilateral tumor with contralateral regional lymph node
involvement; or midline tumor with bilateral extension by
inﬁltration (unresectable) or by lymph node involvement
4 Any primary tumor with dissemination to distant lymph nodes,
bone, bone marrow, liver, skin and/or other organs (except as
deﬁned for stage 4S)
4S Localized primary tumor (as deﬁned for stage 1, 2A or 2B),
with dissemination limited to skin, liver, and/or bone marrow
Reproduced with permission. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of
the international criteria for neuroblastoma diagnosis, staging, and response to
treatment. J Clin Oncol 11:1466e1477, 1993.
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charged home after an uneventful recovery.
Final pathology revealed the mass to be a mature ganglioneur-
oma. All lymph nodes were reactive. Urine catecholamines were
normal but urine VMA was elevated to 8.7 mg/g Cr which was
consistent with the diagnosis of ganglioneuroma. These results
were only available post-operatively.
The patient was seen 2 weeks following discharge and reported
a return of full intestinal function.2. Discussion
The management of incidentally discovered adrenal masses has
become a topic of signiﬁcant discussion in an era when radiologic
imaging is increasingly common. Their incidence, radiologic, and
clinical characteristics have been extensively addressed in the adult
surgical literature, however, very little data regarding their man-
agement in children is available. This may be due to a truly lower
incidence of these masses, but also from less frequent use of CT
scanning in children.
The differential diagnosis of an adrenal mass includes functional
lesions such as pheochromocytoma, cortisol or sex-steroid pro-
ducing adenomas, aldosteronoma, adrenal cortical tumors, and
metastatic malignancy. In children neuroblastoma, ganglioneuro-
blastoma, and ganglioneuroma must also be included.In reviewing the literature on incidentally discovered adrenal
masses among children, we found only one review. This study
focused on masses identiﬁed in children with congenital adrenal
hyperplasia and concluded that surgical resection is rarely indi-
cated due to an extremely low incidence of malignancy [1]. Given
the highly selected population included in this study, its results are
not broadly applicable.
The workup of an adrenal mass should determine which pa-
tients would beneﬁt from adrenalectomy by assessing hormonal
activity and the probability of malignancy. In the elective setting,
this includes a low dose dexamethasone suppression test or 24 h
urine cortisol level as the initial test for cortisol-producing ade-
nomas. Twenty-four hour fractionated urine metanephrines and
catecholamines are used to evaluate for pheochromocytoma and a
plasma aldosterone to renin ratio and serum electrolytes are the
tests of choice for aldosteronomas. When sex-steroid production is
suspected 24 h urine 17-ketosteroids should be measured.
Evaluation of malignant potential is more difﬁcult and is usually
based on size and other imaging characteristics. Findings con-
cerning for malignancy are inhomogeneity, irregular borders, in-
vasion into surrounding structures, associated lymphadenopathy,
and larger size. Benign adenomas are differentiated from adrenal
cortical carcinoma with 96.9% speciﬁcity using 20 Hounsﬁeld units
as a cut-off value for attenuation. This distinction is only possible
with noncontrast CT scans because the enhancement of benign
adenomas overlaps with that of malignant lesions on standard
contrast scans [2].
There is no consensus for identifying malignant lesions based on
size. One study reported a 4 cm cutoff had 93% sensitivity for
detecting adrenal carcinoma after demonstrating adenomas were
signiﬁcantly smaller than carcinomas (mean 3.5 vs. 7.5 cm,
p < 0.001) [3]. Some sources suggest resection of all lesions greater
than 3 cm, while others reported 4 cm lesions warrant resection
[4,5]. The NIH guidelines for adrenal incidentalomas state that
resection is not necessarily indicated for lesions >4 cm without
other concerning characteristics as described above. They do,
however, suggest resection for masses >6 cm [6].
Pheochromocytomas are difﬁcult to manage because of their
propensity for hormonal activity. In children, they have a higher
incidence of malignancy compared to adults (47% vs. 10%). Size
greater than 6 cm is an independent predictor of malignancy [7].
Table 2
Image deﬁned risk factors for abdominal and pelvic neuroblastic tumors.
Tumor inﬁltrating the porta hepatis and/or hepatoduodenal ligament
Tumor encasing branches of the superior mesenteric artery at the mesenteric
root
Tumor encasing the origin of the celiac axis, and/or of the superior mesenteric
artery
Tumor invading one or both renal pedicles
Tumor encasing the aorta and/or vena cava
Tumor encasing the iliac vessels
Pelvic tumor crossing the sciatic notch
Adapted with permission. Monclair T, Brodeur GM, Ambros PF, et al. The Interna-
tional Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
J Clin Oncol 2009;27:298e303.
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classic presentation of episodic hypertension, palpitations, and
headache is less common that previously thought. One study re-
ported these symptoms in only 64%, 53%, and 47% of cases,
respectively [7]. Another study demonstrated hypertension in
only 59% of patients [8].
Neurogenic tumors are challenging to manage because they
exhibit a broad spectrum of clinical behavior ranging from
aggressive neuroblastomas to benign ganglioneuromas. The diag-
nosis typically requires histologic conﬁrmation by tumor biopsy.
Once neuroblastoma is diagnosed, accurate risk stratiﬁcation en-
sures appropriate treatment. This is a complex endeavor requiring
assessment of clinical stage in conjunction with patient age, tumor
histology, and genetics. Appropriate staging requires bone marrow
aspiration, I-123 MIBG scan, and a CT scan or MRI of the abdomen
and pelvis.
The International Neuroblastoma Staging System stages patients
using operative ﬁndings and the extent of tumor resection (Table 1)
[9]. Risk increases from stage 1 to 4, except for stage 4S disease.
These patients must be less than 12 months of age and have
localized primary tumors with metastatic disease limited to the
skin, liver, and bone marrow. Despite their advanced disease, these
patient’s have a 3 year overall survival of 85% [10].
There are two major criticisms of the INSS; the patient’s stage is
not known preoperatively and staging is dependent on how
aggressive individual surgeons are in obtaining complete tumor
resection. Image Deﬁned Risk Factors (IDRFs) which predict the
likelihood of complete resection and post-operative complications
have been described (Table 2) [11,12]. For abdominal neuroblas-
tomas, complete resection was possible in 77.9% vs. 47.2% of
patients without and with IDRFs, respectively. Furthermore, post-
operative complications occurred more frequently in patients with
IDRFs than those without IDRFs (12% vs. 3.3%) [11].
The International Neuroblastoma Risk Group (INRG) used these
IDRFs to design a preoperative staging system. Patients are grouped
according to the presence of IDRFs and disseminated disease
(Table 3). L1 INRG stage has improved event free and overallTable 3
International Neuroblastoma Risk Group staging system.
Stage Deﬁnition
L1 Localized tumor not involving vital structures as deﬁned by image-
deﬁned risk factors and conﬁned to one body compartment
L2 Locoregional tumor with presence of one or more image deﬁned risk
factors
M Distant metastatic disease (except stage MS)
MS Metastatic disease in children younger than 18 months with metastases
conﬁned to skin, liver, and/or bone marrow
Reproduced with permission. Monclair T, Brodeur GM, Ambros PF, et al. The In-
ternational Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force
report. J Clin Oncol 2009;27:298e303.survival compared to INRG stage L2 or M. The relative risks of these
groups corresponded to INSS stages [12,13]. The beneﬁt of this
system is that patients with incompletely resectable disease can be
identiﬁed preoperatively and neoadjuvant therapy may increase
the chance of complete resection.
Had our patient’s lesion been a neuroblastoma, it would be L1
by INRG staging, which portends a high probability of complete
resection and lower incidence of post-operative complications.
The lesion met criteria for resection based on the best available
data for adrenal incidentalomas. Undertaking simultaneous lysis
of adhesions and excisional biopsy was both therapeutic and
diagnostic for this patient in whom intestinal preservation was
essential.
3. Conclusion
The paucity of data for pediatric incidental adrenal masses and
the concurrent obstruction made management of this patient
challenging. His successful outcome was possible through analysis
of the adult data regarding incidental adrenal masses, an under-
standing of the complexities of neuroblastoma staging, and being
cognizant of the need to prevent intestinal resection in a patient
with shortened intestinal length. With the use of cross-sectional
imaging modalities increasing, there is a need for more data on the
management of incidentally discovered abnormalities in the pedi-
atric population.
Disclosures
The authors have no disclosures to report.
References
[1] Lightner ES. The adrenal incidentaloma: a pediatric perspective. Am J Dis Child
1993;147:1274e6.
[2] Hamrahian AH, Loachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H,
Levin HS, et al. Clinical utility of noncontrast computed tomography attenu-
ation value (hounsﬁeld units) to differentiate adrenal adenomas/hyperplasias
from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab
2005;90:871e7.
[3] Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on
adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian
Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637e44.
[4] Bencsik Z, Szabolcs I, Goth M, Voros A, Kaszas I, Gonczi J, et al. Incidentally
detected adrenal tumours (incidentalomas): histological heterogeneity and
differentiated therapeutic approach. J Intern Med 1995;237:585e9.
[5] Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally
discovered adrenal tumors: an institutional perspective. Surgery 1991;110:
1014e21.
[6] Management of the clinically inapparent adrenal mass (“incidentaloma”). NIH
Consensus State-of-the Science Statement February 2002;19(2).
[7] Pham TH, Moir C, Thompson GB, Zarroug AE, Hamner CE, Farley D, et al.
Pheochromocytoma and paraganglioma in children: a review of medical and
surgical management at a tertiary care center. Pediatrics 2006;118:1109e17.
[8] Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Cir-
cumstances of discovery of phaeochromocytoma; a retrospective study of 41
consecutive patients. Eur J Endocrinol 2004;150:681e6.
[9] Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al.
Revisions of the international criteria for neuroblastoma diagnosis, staging,
and response to treatment. J Clin Oncol 1993;11:1466e77.
[10] Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI,
et al. Prognostic signiﬁcance of age, MYCN oncogene ampliﬁcation, tumor cell
ploidy, and histology in 110 infants with stage D(S) neuroblastoma; the pe-
diatric oncology group experienceda pediatric oncology group study. J Clin
Oncol 1998;16:2007e17.
[11] Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, et al.
Surgical risk factors in primary surgery for localized neuroblastoma: the
LNESG1 study of the European International Society of Pediatric Oncology
Neuroblastoma Group. J Clin Oncol 2005;23:8483e9.
[12] Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al.
The International Neuroblastoma Risk Group (INRG) staging system: an INRG
Task Force report. J Clin Oncol 2009;27:298e303.
[13] Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al.
The International Neuroblastoma Risk Group (INRG) classiﬁcation system: and
INRG Task Force report. J Clin Oncol 2009;27:289e97.
